{"id":"W2783829013","doi":"10.1016/j.jaad.2018.01.017","title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)","year":2018,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sanofi Genzyme; LEO Pharma; Dermira; Vanda Pharmaceuticals; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Roivant Sciences; Celgene; Genentech; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Pfizer; King's College London; Galderma; Eli Lilly and Company","keywords":"Medicine; Eczema Area and Severity Index; Placebo; Atopic dermatitis; Adverse effect; Randomized controlled trial; Clinical endpoint; Internal medicine; Placebo-controlled study; Gastroenterology; Dermatology; Double blind; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004380601,0.0003450194,0.004448553,0.0003712623,0.0001308556,0.00001260032,0.0003853189,0.0002094563,0.00003646483],"category_scores_gemma":[0.001010723,0.000207744,0.0003873091,0.0003231059,0.001884926,0.0002016883,0.0001082659,0.0006278662,0.000001543589],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000403624,"about_ca_system_score_gemma":0.0002874791,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003990945,"about_ca_topic_score_gemma":0.000009611429,"domain_scores_codex":[0.9952517,0.001358387,0.002223842,0.0002938681,0.0004451224,0.0004270539],"domain_scores_gemma":[0.9957065,0.001208156,0.002327282,0.0002275036,0.0002041296,0.0003264521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9852263,0.001537449,0.00773649,0.00008914383,0.0009741254,0.0001515257,0.0007051021,0.00002242774,0.0009044553,0.00007811008,0.0008359529,0.001738957],"study_design_scores_gemma":[0.9683586,0.003447291,0.01477239,0.0005320233,0.0009126646,0.006688473,0.0002069618,0.002177981,0.002415798,0.0001557835,0.0001222203,0.0002098332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835728,0.0007798948,0.0003737892,0.01251653,0.000113278,0.002511553,0.00002610036,0.00001136766,0.00009462149],"genre_scores_gemma":[0.9968925,0.0003620359,0.0004017283,0.002155524,0.00009739819,0.00003869064,0.000005327362,0.00002306369,0.00002378278],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01686768,"threshold_uncertainty_score":0.8471555,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009610947437418426,"score_gpt":0.3044593541179478,"score_spread":0.2948484066805294,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}